Regulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged rats

Neurobiology of Aging

Volumn 31, Issue 6, 2010, Pages 1010-1019

  Hu, Yaer ^a   Wang, Zimei ^a   Zhang, Rui ^a   Wu, Pingping ^a   Xia, Zongqin ^a   Orsi, Antonia ^b   Rees, Daryl ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Phytopharm plc   (United Kingdom)

Author keywords

Aged animals; Learning and memory; M1 receptor cDNA transfected CHO cell line (CHOm1 cell line); MRNA of M1 receptor (m1 mRNA); MRNA stability; Muscarinic M1 receptor (M1 receptor); Smilagenin; Y maze avoidance test

Indexed keywords

5 BETA, 20 ALPHA, 22 ALPHA 25 SPIROSTAN 3 BETA OL; ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; MESSENGER RNA; MUSCARINIC M1 RECEPTOR; RADIOLIGAND; SAPOGENIN; SMILAGENIN; UNCLASSIFIED DRUG; ATROPINE; CHOLINESTERASE; DIAMINOBENZIDINE; MUSCARINIC RECEPTOR BLOCKING AGENT; SARSASAPOGENIN; SPIROSTAN DERIVATIVE; TACRINE; TRITIUM;

AGED; AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARAGUS; BINDING ASSAY; BINDING SITE; BRAIN CORTEX; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FEMALE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LEARNING; LIGAND BINDING; MALE; MAZE TEST; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; RECEPTOR DENSITY; RNA STABILITY; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; BINDING COMPETITION; BRAIN; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; MEMORY DISORDER; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

3,3'-DIAMINOBENZIDINE; AGING; ANALYSIS OF VARIANCE; ANIMALS; ATROPINE; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CHO CELLS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MAZE LEARNING; MEMORY DISORDERS; MUSCARINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RNA, MESSENGER; SPIROSTANS; TACRINE; TRANSFECTION; TRITIUM;

EID: 77951976388     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.06.008     Document Type: Article

References (40)

1. Bai Y., Lu H., Machida C.A. CRM 1-mediated degradation and agonist-induced down-regution of β-adrenergic receptor mRNAs. Biochim. Biophys. Acta 2006, 1763:1076-1089.
2. Balmer, L.A., Beveridge, D.J., Jazayeri, J.A., 2001. Thomson AM, Walker CE, Leedman PJ. Identification of a novel AU-rich element in the 3′ untranslated region of epidermal growth factor receptor mRNA that is the targe for regulated RNA-binding proteins. Mol. Cell. Biol. 21, 2070-2084.
3. Beach T.G. Muscarinic agonists as preventative therapy for Alzheimer's disease. Curr. Opin. Invest. Drugs 2002, 3:1633-16366.
4. Berger A., Stierkorb E., Nickenig G. The role of the AUUUUA hexamer of the post-transcriptional rgulation of the AT1 receptor mRNA stability. Biochem. Biophys. Res. Commun. 2005, 330:805-812.
5. Blenow K., deLeon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
6. Buckley N.J., Bonner T.I., Brann M.R. Localization of a family of muscarinic receptor mRNAs in rat brain. J. Neurosci. 1988, 8:4646-4652.
7. Buckley N.J., Bonner T.I., Buckley C.M., Brann M.R. Antagonist binding properties of five cloned muscarinic receptor expressed in CHO-K1 cells. Mol. Pharmacol. 1989, 35:469-476.
8. Budd D.C., Rae A., Tobin A.B. Activation of the mitogen-activated protein kinase pathway by a Gq/11-coupled muscarinic receptor is independent of receptor internalization. J. Biol. Chem. 1999, 274:12355-12360.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
10. Danner S., Frank M., Lohse M.J. Agonist regulation of human β2-adrenergic receptor mRNA stability occurs via a specific AU-rich element. J. Biol. Chem. 1998, 273:3223-3229.
11. Deschenes-Furry J., Perrone-Bizzozero N., Jasmin B.J. The RNA-binding protein HuD: a regulator of neuronal differentiation, maintenance and plasticity. BioEssays 2006, 28:822-833.
12. Dreyfuss G., Kim V.N., Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 2002, 3:195-205.
13. Eberhardt W., Doller A., Akool el-S., Pfeilshifter J. Modulation of mRNA stability as a novel therapeurtic approach. Pharmacol. Ther. 2007, 114:56-73.
14. Ellman G.L., Courtney U.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
15. Flynn D.D., Ferrari-Dileo G., Mash D.C., Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995, 64:1888-1891.
16. Fonnum F. Radiochemical microassays for the determination of choline acetyltransferase and acetylcholinsterase activities. Biochem. J. 1969, 115:465-472.
17. Fraser C.M., Lee N.H. Regulation of muscarinic receptor expression by changes in mRNA stability. Life Sci. 1995, 56:899-906.
18. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol. 2007, 8:113-126.
19. Haddad E.B., Rousell J., Lindsay M.A., Barnes P.J. Synergy between tumor necrosis factor alpha and interleukin 1beta in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J. Biol. Chem. 1996, 271:32586-32592.
20. Haddad E.B., Rousell J., Mak J.C., Barnes P.J. Long-term carbachol treatment-induced down-regulation of muscarinic M2-receptors but not m2 receptor mRNA in a human lung cell line. Br. J. Pharmacol. 1995, 116:2027-2032.
21. Hellweg R., Fischer W., Hock C., Gage F.H., Bjorklund A., Thornen H. Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments. Brain Res. 1990, 537:123-130.
22. Herrmann N. Treatment of moderate to severe Alzheimer's disease: rationale and trial design. Can. J. Neurol. Sci. 2007, 34(Suppl. 1):S103-S108.
23. Hollams E.M., Giles K.M., Thomson A.M., Leedman P.J. mRNA stability and the control of gene expression: implications for human disease. Neurochem. Res. 2002, 27:957-980.
24. Hu Y.E., Xia Z.Q., Sun Q.X., Orsi A., Rees D. A new approach to the pharmacological regulation of memory: sarsasapogenin improves memory by elevating the low muscarinic-acetylcholine receptor density in brains of memory-deficit rat models. Brain Res. 2005, 1060:26-39.
25. Klafke H.W., Staufenbiel M., Kornhuber J., Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006, 129:2840-2855.
26. Leanza G., Muir J., Nilsson O.G., Wiley R.G., Dunnett S.B., Bjorklund A. Selective immunolesioning of the basal forebrain cholinergic system disrupts short-term memory in rats. Eur. J. Neurosci. 1996, 8:1535-1544.
27. Lee N.H., Malek R.L. Nerve growth factor regulation of m4 muscarinic receptor mRNA stability but not gene transcription requires mitogen-activated protein kinase activity. J. Biol. Chem. 1998, 273:22317-22325.
28. Lleo A., Greenberg S.M., Growdon J.H. Current pharmacotherapy for Alzheimer's disease. Ann. Rev. Med. 2006, 57:513-533.
29. Molinoff P.B., Wolfe B.B., Weiland G.A. Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes. Life Sci. 1981, 29:427-443.
30. Parasi S., Collogby S.J., Firbank M.J., Perry E.K., Wyper D.J., Owens J., McKeith I.G., Williams E.D., O'Brien J.T. Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R,R)123I-QNB SPECT. J. Neurol. 2007, 254:907-913.
31. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney, pp. C20-30. 2nd ed.
32. Qi C., Pekala H. The influence of mRNA stability on glucose transporter (GLUT1) gene expression. Biochem. Biophys. Res. Commun. 1999, 263:265-269.
33. 4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997, 26:341-350.
34. Shaw G., Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986, 46:659-667.
35. Steel M.C., Buckley N.J. Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study. Mol. Pharmacol. 1993, 43:694-701.
36. Stoehr J.D., Mobley S.L., Roice D., Brooks R., Baker L.M., Wiley R.G., Wenk G.L. The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol. Learn. Memory 1997, 67:214-227.
37. Stope M.B., Kunkel C., Kories C., Schmidt M., Michel M.C. Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. Biochem. Pharmacol. 2003, 66:2099-2105.
38. Terada T., Inui K. Gene expression and regulation of drug transporters in the intestine and kidney. Biochem. Pharmacol. 2007, 73:440-449.
39. Wang S.Z., Zhu S.Z., Mash D.C., el-Fakahany E.E. Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. Brain Res. Mol. Brain Res. 1992, 16:64-70.
40. Young A.B., Penney J.B. Neurotransmitter receptors in Alzheimer disease. Alzheimer Disease 1994, 293-303. Raven Press, New York. R.D. Terry, R. Katzman, K.L. Bick (Eds.).